BAC vs CME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BAC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAC and CME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAC and CME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bank of America is the second-largest US bank by assets, behind JPMorgan Chase. The company is one of the four mega-bank holding companies (along with JPMorgan, Citigroup, and Wells Fargo) and operates across four main reporting segments. Consumer Banking is the largest retail bank in the US by deposits, serving over 60 million customers through ~3,800 branches. Global Wealth and Investment Management is one of the largest US wealth managers (anchored by Merrill Lynch). Global Banking provides commercial banking, treasury services, and investment banking to corporate and institutional clients. Global Markets provides trading services across fixed income, equities, and commodities.

Full BAC guide

CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results.

Full CME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAC drivers: Net interest income from deposit franchise; Investment banking and trading recovery.
• CME drivers: Record trading volumes; Interest-rate and volatility franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Credit quality is the eternal bank risk; consumer and commercial credit losses rise cyclically. For CME, revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAC if you believe its drivers more; CME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAC and CME guides.

BAC. BAC trades at a modest multiple typical of large US banks, about 12.5x trailing and 10x forward earnings after the October 2026 sell-off. The valuation balances the deposit franchise, rising net interest income, and wealth growth against a costly AML settlement, softer trading, and credit-cycle uncertainty. Analysts still rate it a strong buy with an average target near $63, and the next report is due January 15, 2027.

CME. CME has rerated upward since mid-2026, gaining ~23% in three months, so the trailing P/E has moved from about 21 to about 25 even though second-quarter revenue grew less than 1%. Analysts' mean target of ~$293 sits close to the share price, consistent with a hold consensus. The regular dividend alone yields ~1.8%; the variable year-end dividend, declared each December, adds to that and makes the headline blended yield materially higher.

Headline figures (approximate, October 2026): BAC shows revenue (ttm) ~$115 billion; Q3 2026 revenue up ~7% YoY, net income (ttm) ~$30.8 billion; Q3 2026 ~$6.5 billion (down from ~$8.0 billion), eps ~$4.19 (TTM); Q3 2026 $0.91 reported, ~$1.08 ex-settlement, vs ~$1.10 expected, net interest income ~$16.6 billion in Q3 2026 (up ~8% YoY); net interest yield 2.16%; CME shows revenue (ttm) ~$6.76B (FY2025 ~$6.52B); Q2 2026 +~0.8% y/y, net income (ttm) ~$4.26B, profit margin ~63%, operating margin ~65%, eps (ttm / 2026 est.) ~$11.79 trailing; ~$12.31 consensus for 2026.

BAC and CME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAC and CME exposure against your real portfolio. It is not an investment adviser.